PT-141 10mg

10mg/ml subcutaneous injection provided in a 2ml vial.

“Melanocortins in the treatment of male and female sexual dysfunction. Melanocortinergic agents are currently being investigated therapy for erectile dysfunction. Studies using animal for a possible therapeutic role in male and female sexual models have demonstrated that pre-copulatory behaviors dysfunction. These investigations were sparked by in female rats analogous to sexual arousal are evoked, and findings that systemic administration of a synthetic analog preliminary clinical data also suggest a role in promoting of alpha-MSH, MT-II, causes penile erections in a variety sexual desire and arousal in women. Based on of species, including humans. Several other bremelanotide clinical experience, administration of a melanocortinergic agents including HP-228, THIQ, and melanocortin agonist is well tolerated and not associated bremelanotide (PT 141) have since been shown to have the hypotension observed with phosphodiesterase-S erectogenic properties thought to be due to binding inhibitors currently used to treat erectile dysfunction. This to melanocortin receptors in the central nervous system, review discusses investigations of melanocortin agonists for particularly the hypothalamus. Bremelanotide, a nasally the treatment of sexual dysfunction with emphasis on administered synthetic peptide, is the only proposed sites and mechanisms of action in the central melanocortinergic agent that has been clinically studied in nervous system that appear to be involved in both males and females. Data from Phase II clinical trials of melanocortinergic modulation of sexual function. bremelanotide support the use of melanocortin based Shadiack, Annette & D Sharma, Shubh & C Earle, Dennis & Spana, Carl & J Hallam, Trevor. (2007). Melanocortins in the Treatment of Male and Female Sexual Dysfunction. Current topics in medicinal chemistry, 7. 1137-44.”